A Phase 2b multicenter, randomized, double-blind, placebo-controlled study dose-finding trial for RGT-075 in patients with obesity or overweight with weight-related comorbidities.
Latest Information Update: 16 Jan 2025
Price :
$35 *
At a glance
- Drugs RGT 075 (Primary)
- Indications Obesity
- Focus Therapeutic Use
- Acronyms COMO-1
- 16 Jan 2025 New trial record
- 10 Jan 2025 Regor announced the initiation of the COMO-1 dose-finding trial for RGT-075. with topline data from this Phase 2b study are expected at the end of 2025.